44 related articles for article (PubMed ID: 18448563)
1. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
Ray-Coquard I; Le Cesne A; Whelan JS; Schoffski P; Bui BN; Verweij J; Marreaud S; van Glabbeke M; Hogendoorn P; Blay JY
Oncologist; 2008 Apr; 13(4):467-73. PubMed ID: 18448563
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma.
Eilber FC; Brennan MF; Eilber FR; Eckardt JJ; Grobmyer SR; Riedel E; Forscher C; Maki RG; Singer S
Ann Surg; 2007 Jul; 246(1):105-13. PubMed ID: 17592298
[TBL] [Abstract][Full Text] [Related]
3. Single-cell landscape of undifferentiated pleomorphic sarcoma.
Lu Y; Chen D; Wang B; Chai W; Yan M; Chen Y; Zhan Y; Yang R; Zhou E; Dai S; Li Y; Dong R; Zheng B
Oncogene; 2024 May; 43(18):1353-1368. PubMed ID: 38459120
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors in sarcoma treatment.
Kyriazoglou A; Gkaralea LE; Kotsantis I; Anastasiou M; Pantazopoulos A; Prevezanou M; Chatzidakis I; Kavourakis G; Economopoulou P; Nixon IF; Psyrri A
Oncol Lett; 2022 Jun; 23(6):183. PubMed ID: 35527786
[TBL] [Abstract][Full Text] [Related]
5. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective.
Kondo T
Cancer Sci; 2021 Mar; 112(3):953-961. PubMed ID: 32986888
[TBL] [Abstract][Full Text] [Related]
6. The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas.
Wang X; Yeo RX; Hogg PJ; Goldstein D; Crowe P; Dilda PJ; Yang JL
Oncotarget; 2020 Jan; 11(1):46-61. PubMed ID: 32002123
[TBL] [Abstract][Full Text] [Related]
7. Low HIF-1α and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently.
Rot S; Taubert H; Bache M; Greither T; Würl P; Holzhausen HJ; Eckert AW; Vordermark D; Kappler M
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513863
[TBL] [Abstract][Full Text] [Related]
8. Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review.
Riedel RF; Jones RL; Italiano A; Bohac C; Thompson JC; Mueller K; Khan Z; Pollack SM; Van Tine BA
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30388821
[TBL] [Abstract][Full Text] [Related]
9. Systemic Treatment for Adults with Synovial Sarcoma.
Desar IME; Fleuren EDG; van der Graaf WTA
Curr Treat Options Oncol; 2018 Mar; 19(2):13. PubMed ID: 29516254
[TBL] [Abstract][Full Text] [Related]
10. EGFR is involved in dermatofibrosarcoma protuberans progression to high grade sarcoma.
Osio A; Xu S; El Bouchtaoui M; Leboeuf C; Gapihan G; Lemaignan C; Bousquet G; Lebbé C; Janin A; Battistella M
Oncotarget; 2018 Feb; 9(9):8478-8488. PubMed ID: 29492209
[TBL] [Abstract][Full Text] [Related]
11. Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma.
Yang JL; Gupta RD; Goldstein D; Crowe PJ
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28556791
[No Abstract] [Full Text] [Related]
12. Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.
Wang X; Goldstein D; Crowe PJ; Yang M; Garrett K; Zeps N; Yang JL
Oncotarget; 2016 Apr; 7(16):21496-509. PubMed ID: 26909593
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy.
Aggerholm-Pedersen N; Demuth C; Safwat A; Meldgaard P; Kassem M; Sandahl Sorensen B
Stem Cells Int; 2016; 2016():9601493. PubMed ID: 26788073
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of childhood cancer: Biomarkers and novel therapies.
Saletta F; Wadham C; Ziegler DS; Marshall GM; Haber M; McCowage G; Norris MD; Byrne JA
BBA Clin; 2014 Jun; 1():59-77. PubMed ID: 26675306
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
Morgan SS; Cranmer LD
BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
[TBL] [Abstract][Full Text] [Related]
16. The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.
Rocchi L; Caraffi S; Perris R; Mangieri D
Biosci Rep; 2014 Nov; 34(6):e00147. PubMed ID: 25236925
[TBL] [Abstract][Full Text] [Related]
17. Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas.
Morgan SS; Nagle RB; Cranmer LD
Clin Sarcoma Res; 2014 Jan; 4(1):2. PubMed ID: 24484617
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Sharma S; Takyar S; Manson SC; Powell S; Penel N
BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
[TBL] [Abstract][Full Text] [Related]
19. Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?
Pennacchioli E; Tosti G; Barberis M; De Pas TM; Verrecchia F; Menicanti C; Testori A; Mazzarol G
Clin Exp Metastasis; 2012 Oct; 29(7):757-73. PubMed ID: 22699363
[TBL] [Abstract][Full Text] [Related]
20. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.
Przybyl J; Jurkowska M; Rutkowski P; Debiec-Rychter M; Siedlecki JA
Sarcoma; 2012; 2012():249219. PubMed ID: 22550415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
